Charles B Holmes

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa
    Charles B Holmes
    Division of Infectious Disease, Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 36:652-62. 2003
  2. ncbi request reprint Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost
    Charles B Holmes
    Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 42:1772-80. 2006
  3. ncbi request reprint CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment
    Charles B Holmes
    Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 42:464-9. 2006
  4. pmc First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA
    AIDS 25:479-92. 2011
  5. pmc Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting
    Maunank Shah
    Department of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 52:145-51. 2009
  6. ncbi request reprint Comparative costs of inpatient care for HIV-infected and uninfected children and adults in Soweto, South Africa
    Leena S Thomas
    School of Public Health, University of the Witwatersrand, and Gauteng Department of Health, Johannesburg, South Africa
    J Acquir Immune Defic Syndr 46:410-6. 2007
  7. ncbi request reprint The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy
    José R Valdez Madruga
    Centro de Referência e Treinamento DST AIDS, Sao Paulo, Brazil
    HIV Clin Trials 8:381-90. 2007
  8. ncbi request reprint Response to "CD4 cell count natural history and informative censoring in sub-Saharan Africa"
    Charles B Holmes
    J Acquir Immune Defic Syndr 44:491. 2007
  9. ncbi request reprint Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
    Jose R Arribas
    Internal Medicine Service, Hospital de La Paz, Madrid, Spain
    J Acquir Immune Defic Syndr 47:74-8. 2008

Research Grants

Detail Information

Publications9

  1. ncbi request reprint Review of human immunodeficiency virus type 1-related opportunistic infections in sub-Saharan Africa
    Charles B Holmes
    Division of Infectious Disease, Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 36:652-62. 2003
    ..Policies regarding the type and timing of opportunistic infection prophylaxis may be region specific and urgently require further study...
  2. ncbi request reprint Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost
    Charles B Holmes
    Divisions of Infectious Disease and General Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Clin Infect Dis 42:1772-80. 2006
    ..Our objectives were to project the tradeoffs regarding life expectancy, cost, and cost-effectiveness of these ART regimens for NVP-exposed, HIV-infected women in South Africa...
  3. ncbi request reprint CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment
    Charles B Holmes
    Divisions of Infectious Disease, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Acquir Immune Defic Syndr 42:464-9. 2006
    ..To determine the rate of CD4 decline and the incidence of opportunistic infections (OIs) among antiretroviral therapy-naive South African HIV-infected patients and inform timing of OI prophylaxis...
  4. pmc First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, Boston, 02114, USA
    AIDS 25:479-92. 2011
    ..nevirapine-based antiretroviral therapy (ART) among women previously exposed to single-dose nevirapine to prevent mother-to-child HIV transmission. However, lopinavir/ritonavir is 12 times costlier than nevirapine...
  5. pmc Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting
    Maunank Shah
    Department of Medicine, Johns Hopkins University Center for Tuberculosis Research, Baltimore, MD 21231, USA
    J Acquir Immune Defic Syndr 52:145-51. 2009
    ..Effective tuberculosis (TB) control in HIV-prevalent settings is hindered by absence of accurate, rapid TB diagnostic tests. We evaluated the accuracy of a urine lipoarabinomannan (LAM) test for TB diagnosis in South Africa...
  6. ncbi request reprint Comparative costs of inpatient care for HIV-infected and uninfected children and adults in Soweto, South Africa
    Leena S Thomas
    School of Public Health, University of the Witwatersrand, and Gauteng Department of Health, Johannesburg, South Africa
    J Acquir Immune Defic Syndr 46:410-6. 2007
    ..HIV/AIDS creates a massive burden of care for health systems. A better understanding of the impact of HIV infection on health care utilization and costs may enable better use of limited resources...
  7. ncbi request reprint The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy
    José R Valdez Madruga
    Centro de Referência e Treinamento DST AIDS, Sao Paulo, Brazil
    HIV Clin Trials 8:381-90. 2007
    ..Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) with stavudine (d4T), in combination with lamivudine (3TC) and efavirenz (EFV), and an ongoing 336-week open-label extension phase...
  8. ncbi request reprint Response to "CD4 cell count natural history and informative censoring in sub-Saharan Africa"
    Charles B Holmes
    J Acquir Immune Defic Syndr 44:491. 2007
  9. ncbi request reprint Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis
    Jose R Arribas
    Internal Medicine Service, Hospital de La Paz, Madrid, Spain
    J Acquir Immune Defic Syndr 47:74-8. 2008
    ..As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important...

Research Grants1

  1. Impact of HIV-related infections and ART in South Africa
    Charles Holmes; Fiscal Year: 2006
    ..He is mentored by two senior investigators with an extremely strong record of mentoring junior investigators and guiding them to become successful physician scientists. ..